What is Type 1 Diabetes TrialNet?

Type 1 Diabetes TrialNet is a group of studies looking at the development, prevention and early treatment of type 1 diabetes.

TrialNet was established in response to the Surgeon General's Report Healthy People 2010. This report identified diabetes as a national health objective for the Nation. In response to the report, Congress created the Diabetes Research Working Group (DRWG) to develop a plan for diabetes research. One recommendation of the DRWG was to conduct additional research studies (clinical trials) to prevent type 1 diabetes.

TrialNet is jointly funded by:

• The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• The National Institute of Allergy and Infectious Diseases (NIAID)
• The National Institute of Child Health and Human Development (NICHD)
• The National Center for Research Resources at the NIH, which provides support through its General Clinical Research Centers (GCRC) Program.
• Juvenile Diabetes Research Foundation International (JDRF).
• American Diabetes Association (ADA)

TrialNet will conduct multiple clinical trials with investigators from 18 Clinical Centers in the United States, Canada, Finland, United Kingdom, Italy, Germany, Australia and New Zealand. Over the course of TrialNet, several studies will be conducted in patients with newly diagnosed (new onset) type 1 diabetes, as well as in relatives of people with type 1 diabetes who are at greater risk of developing the disease.

There will be two types of studies:

• Natural History Studies which will provide information about risk factors associated with developing type 1 diabetes.
• Diabetes Intervention Studies which will test either treatments to delay or prevent the onset of type 1 diabetes, or test treatments to preserve remaining insulin secretion in people recently diagnosed with type 1 diabetes.

More Information:  http://www2.diabetestrialnet.org/tnet